Most families affected by cancer have experienced the tragic burden of dealing with the toxic effects of therapy - pain, limted dosing and high costs. The U. S. government has recognized the issue and has made the elimination of side effects one of 10 national priorities as part of the recent bipartisan U.S. Cancer Moonshot Panel Report. The report said:
"Reduction in the deleterious symptoms of cancer and its treatment will encourage patients to continue with and benefit from recommended therapy and clinical trials, maintain optimal well-being, and stay engaged in family and societal roles. Furthermore, reduction in moderate-to-severe symptoms will lead to marked decrease in cancer care costs related to emergency department visits, urgent care, and unplanned hospitalizations and readmissions."
Congress passed the 21st Century Cures Act in December 2016 authorizing $1.8 billion in funding for the Cancer Moonshot over 7 years. That includes an appropriation of $400 million for FY 2019.
Tosk is at the forefront of the Moonshot's ambitious initiative, which is being led by the National Cancer Institute. Tosk’s first drug, TK-90, recently completed human trials that achieved Proof of Concept, and the company plans a second confirming trial beginning in early 2019. A second drug, TK-39, will enter human trials in 2019. Both drugs have benefitted from federal and state research grants. Tosk’s team is poised to transform treatment for the benefit of patients everywhere.
[Your content here]